The spinal muscular atrophy (SMA) market across five Asia-Pacific countries including Australia, China, India, Japan and South Korea is expected to grow at a compound annual growth rate of 23.3% from US$308.6m in 2018 to US$2.5bn in 2028, according to GlobalData, a UK based data analytics and consulting company.
Prevalence of spinal muscular atrophy (SMA) cases in these five countries including India is estimated to escalate from 94,508, as in 2018, to 99,759 cases in 2028, says the company’s recently published report entitled ‘Spinal Muscular Atrophy: Forecast in Asia-Pacific Markets to 2028’.
Increased uptake of the disease-modifying SMA therapies will help in shaping and development of the global SMA market.
SMA is a genetic neuromuscular disorder that leads to loss of motor neurons and results in progressive muscle wasting.
Biogen’s antisense therapy Spinraza (nusinersen) is one among the new disease-modifying SMA therapies that has recently been approved in Japan, Australia, South Korea and China for the treatment of the disease.
Spinraza injection helps in the management of SMA in paediatric and adult patients by increasing the production of survival motor neuron (SMN) protein, whose lack and/or underproduction leads to the disorder. The therapy has shown to produce clinically meaningful improvements in motor function, and survival in the affected children.
Apart from the current therapy, several other disease-modifying treatments for SMA including gene therapy and oral therapy are currently in clinical trials.
The report shows that in 2018, Spinraza accounted for a vast majority of sales across the five growth markets (5GM) including India, Australia, Japan, China and South Korea. However, the company estimates the sales to remain strong only up to 2023.
Global Data projects Spinraza to lose its monopoly in the mid-to-late forecast period (2023–2028), and the launch of pipeline products from 2020 onwards are to be expected to capture significant market share.
The company noted that Novartis’ gene therapy Zolgensma (onasemnogene abeparvovec-xioi) presents a potentially transformative treatment option for SMA.
Unlike multiple intrathecal administrations as required for Spinraza, Zolgensma only needs to be administered by a one-time intravenous infusion.
Zolgensma which has already received approval in the US is expected to emerge as the market leader in the Asia-Pacific region by 2028 with sales of US$1.3bn across the five growth markets.
The launch of Roche’s oral drug for SMA, risdiplam, an SMN2 splicing modifier, is also eagerly anticipated by the company to rise with its non-invasive and easy route of administration.